← brief for 2026-09-13 · Slowing decline

Acute kidney injury during ruxolitinib therapy in pediatric patients with graft-versus-host disease: incidence, associated factors, and histopathological findings in a retrospective cohort study

Key takeaways

Ruxolitinib is a drug given for graft-versus-host disease, a complication after a bone marrow transplant. Researchers looked back through the records of children on this drug to count how many had sudden kidney injury, what made it more likely, and what the kidney tissue looked like under a microscope. No abstract was posted with this record, so the counts are not available here. A look-back study like this shows a link between the drug and kidney trouble, not proof that the drug caused it, because these children are very ill in several ways at once.

Who did this work

Beyza Ural Koluaçık (Akdeniz University) · Sinem Durdaş (Akdeniz University) · Nilden Ünsal (Akdeniz University) · Gülşah Kaya Aksoy (Akdeniz University) · Funda Tayfun Küpesiz (Akdeniz University) · Zeyneb Merve Küçük (Akdeniz University) · Mustafa Koyun (Akdeniz University) · Elif Çomak (Akdeniz University) · Havva Serap Toru (Akdeniz University) · Bahar Akkaya (Akdeniz University) · Osman Alphan KÜPESİZ (Akdeniz University) · Elif Güler (Akdeniz University)

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-12
https://doi.org/10.1080/08880018.2026.2731106